The first 60 days: Plasma cell leukaemia

Below, week by week, is what OnCo's record of Plasma cell leukaemia says about the first two months: the order is typical, the timing is yours to ask about. Plasma cell leukaemia is myeloma in which the cancerous plasma cells spill into the bloodstream in large numbers. It is the most aggressive plasma cell cancer and is treated urgently with several myeloma drugs at once followed by a stem cell transplant. Sections appear only where the record has something to say. Orientation, not medical advice.

Weeks 1 to 2

What happens now

Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.

Biomarkers your report may list

Circulating plasma cells on blood film (5 percent or more) and by flow cytometry Lactate dehydrogenase FISH: del(17p), t(14;16), t(11;14), 1q gain, del(1p)TP53 mutation Renal function and calcium Serum free light chains and M-protein Extramedullary disease on PET-CT

Ask which of these were tested and what the results were; see the report reader for what each value means.

Tests and imaging linked to this cancer

Multiparameter flow cytometry MRD

Weeks 1 to 3

Who is on your team

These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.

A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.

Weeks 2 to 6

Decisions coming up

Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.

1.Primary plasma cell leukaemia, induction NCCN Guidelines: Multiple Myeloma
Bortezomib-based quadruplet (daratumumab with bortezomib, lenalidomide or cyclophosphamide, and dexamethasone), or VTD-PACE-type multi-agent chemotherapy for rapid control, with tumour lysis and renal precautions.
Bortezomib Daratumumab Lenalidomide Cyclophosphamide Dexamethasone Carfilzomib Tumour lysis syndrome (TLS)
2.Consolidation NCCN Guidelines: Multiple Myeloma
Autologous stem cell transplant for all fit patients; tandem autologous or reduced-intensity allogeneic transplant considered in young patients; continuous maintenance after transplant.
Autologous stem cell transplant (high-dose therapy)Allogeneic stem cell transplantation Melphalan (including hepatic delivery system)Lenalidomide Maintenance therapy
3.Secondary plasma cell leukaemia or relapse NCCN Guidelines: Multiple Myeloma
Treated as heavily relapsed myeloma: BCMA or GPRC5D bispecific antibodies, CAR-T where feasible, selinexor or pomalidomide combinations; palliative care early.
Teclistamab Talquetamab Ciltacabtagene autoleucel Selinexor Pomalidomide

Every visit

Questions to ask at each visit

Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.

Newly diagnosed

What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example Circulating plasma cells on blood filmand by flow cytometry, Lactate dehydrogenase, FISH: del, t, t, 1q gain, del, TP53 mutation, Renal function and calcium), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Primary plasma cell leukaemia, Secondary plasma cell leukaemia, Plasma cell leukaemia with high-risk cytogenetics, t, 1q gain).
Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.

Primary plasma cell leukaemia, induction

For my situation (primary plasma cell leukaemia, induction), which of the standard options do you recommend and why?Guideline options include: Bortezomib-based quadruplet (daratumumab with bortezomib, lenalidomide or cyclophosphamide, and dexamethasone), or VTD-PACE-type multi-agent chemotherapy for rapid control, with tumour lysis and renal precautions.
Am I a candidate for Bortezomib, Daratumumab, Lenalidomide or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.

Consolidation

For my situation (consolidation), which of the standard options do you recommend and why?Guideline options include: Autologous stem cell transplant for all fit patients; tandem autologous or reduced-intensity allogeneic transplant considered in young patients; continuous maintenance after transplant.
Am I a candidate for Melphalan (including hepatic delivery system), Lenalidomide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.

Secondary plasma cell leukaemia or relapse

For my situation (secondary plasma cell leukaemia or relapse), which of the standard options do you recommend and why?Guideline options include: Treated as heavily relapsed myeloma: BCMA or GPRC5D bispecific antibodies, CAR-T where feasible, selinexor or pomalidomide combinations; palliative care early.
Am I a candidate for Teclistamab, Talquetamab, Ciltacabtagene autoleucel or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.

Any stage

Are there clinical trials I could join, for example of Teclistamab, Ciltacabtagene autoleucel, Daratumumab, Carfilzomib?Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
I read that “No randomised trials; treatment is extrapolated from high-risk myeloma”. How does that affect my plan?Open problems are where trials and second opinions matter most.
I read that “Secondary plasma cell leukaemia has no effective standard”. How does that affect my plan?Open problems are where trials and second opinions matter most.

From day one

Help that costs nothing

Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.

Any time

What to read next

Words this page and the cancer page use

t(11;14), cyclin D1 and SOX11: The t(11;14) translocation parks the cyclin D1 gene next to the antibody gene's accelerator, flooding the cell with a protein that pushes it through division; a brown nuclear stain for cyclin D1 (plus SOX11) is how mantle cell lymphoma is confirmed, and in myeloma the same translocation marks the patients who respond to venetoclax.
High-risk cytogenetics (myeloma): Chromosome changes such as del(17p), t(4;14), t(14;16) and extra copies of 1q that mark myeloma likely to relapse early.
Leukaemia (tissue type): Cancer of the blood-forming cells in the bone marrow, which flood the blood with immature or abnormal white cells and crowd out normal blood production.
Proteasome inhibitor (bortezomib, carfilzomib, ixazomib): Drugs that block the cell's protein-recycling machine.
Flow cytometry (immunophenotyping): A machine that streams cells one by one past lasers and reads the surface proteins (CD markers) each carries, identifying what kind of cell it is.
M-protein, immunofixation and serum free light chains: Myeloma cells are clones of one antibody-making cell, so they pour a single identical antibody, the M-protein, into the blood; measuring it (and the free light chains that go with it) is how myeloma is diagnosed, how deep a response is judged, and how relapse is caught before symptoms.
TP53-mutated (p53-abnormal): Loss of the p53 'guardian of the genome', the most commonly mutated gene in cancer.
Autologous stem cell transplant (ASCT): High-dose chemotherapy (melphalan in myeloma, BEAM in lymphoma) that would permanently destroy the bone marrow, made survivable by giving the patient back their own previously collected stem cells, which engraft in 10-14 days.
Maintenance therapy: Ongoing, gentler treatment given after the main course has shrunk the cancer, to hold it in check for as long as possible rather than to shrink it further.
Tumour lysis syndrome (TLS): When a treatment kills cancer cells faster than the body can clear their contents, flooding the blood with potassium, phosphate and uric acid and injuring the kidneys and heart.

Every term links to the glossary.